A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
552
ICP-332 will be administered as tablet
ICP-332 Placebo will be administered as tablet
Proportion of subjects achieving at least a 75% reduction in Eczema Area and Severity Index (EASI 75) from Baseline
Time frame: 16 weeks
Proportion of subjects achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 with at least two grades of reduction from Baseline
Time frame: 16 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
RECRUITINGThe Second Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China
RECRUITINGCapital Medical University Affiliated Beijing Chaoyang Hospital
Beijing, Beijing Municipality, China
RECRUITINGPeking University First Hospital
Beijing, Beijing Municipality, China
RECRUITINGCapital Medical University Affiliated Beijing Friendship Hospital
Beijing, Beijing Municipality, China
RECRUITINGPeking University Third Hospital
Beijing, Beijing Municipality, China
RECRUITINGBeijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
RECRUITINGBeijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China
RECRUITINGThe First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
RECRUITINGChongqing Traditional Chinese Medicine Hospital
Chongqing, Chongqing Municipality, China
RECRUITING...and 52 more locations